CCRM Nordic Signs ATMP MoU in Korea

CCRM Nordic Strengthens Global ATMP Collaboration in Korea

During BIO KOREA, CCRM Nordic signed a memorandum of understanding (MoU) with two major South Korean organizations — the Regenerative Medicine Acceleration Foundation (RMAF) and the Council of Advanced Regenerative Medicine (CARM). The agreement marks a significant step forward in strengthening international cooperation in the cell and gene therapy space.

Focus on Joint Innovation and Training

Under the new agreement, the three parties will collaborate on:

• Identifying and planning international ATMP research and development (R&D) projects

• Promoting commercialization of innovative regenerative medicine technologies

• Creating and sharing human resource training programs

The MoU was signed by Jim Lund, CBDO of CCRM Nordic, alongside So Ra Park (President, RMAF) and Duckjoo Lee (President, CARM).

Part of a Growing Global Network

CCRM Nordic’s involvement in this agreement also reinforces its role in the CARM Global Network—a collective of leading organizations in the regenerative medicine sector. Other members include:

• ISCT (International Society for Cell & Gene Therapy): A global leader in translating cell and gene therapy from research to clinical application

• Biocom California: A powerhouse for life science advocacy and industry support in California

• Alliance for Regenerative Medicine (ARM): The international voice of the engineered cell and gene therapy community

• AusBiotech: Australia’s biotech industry body promoting global bioscience commercialization

BIO KOREA: A Global Meeting Point

Held annually since 2006, BIO KOREA has grown into a key international event for the bio-health industry. This year’s event brought together global experts and decision-makers in biotechnology, offering networking opportunities and insights into emerging healthcare technologies.